RATE OF DEPRESSION IN SARS-CoV-2 PNEUMONIA AND HYPERTENSION CASE IN THE MIDDLE ISCHEMIC DISEASE FOUNDATION

Аннотация

COVID-19 diagnosis in the setting of ICU presents certain difficulties, as circulatory failure often masks the clinical manifestations of the underlying disease and complicates its timely diagnosis. It can be caused by typical manifestations of circulatory failure, including shortness of breath (at rest, during exercise), fatigue, tachycardia, tachypnea, wheezing during auscultation, and fluid accumulation in the pleural cavity. The course of ICU in the setting of COVID-19 has its own characteristics. Coronary artery thrombosis in the setting of COVID-19 can develop according to two main mechanisms: first, it manifests itself as a coagulopathy specific to the disease, and second, it manifests itself as a result of systemic inflammation and destabilization of coronary artery atherosclerosis in response to viral infection. The cause of the development of IHD in the context of COVID-19 is an imbalance between myocardial oxygen demand and oxygen delivery against the background of severe respiratory and hemodynamic disorders, as well as spontaneous dissection of the coronary arteries. According to data, IHD is oneofthemain causes ofdeath among patients hospitalized with COVID-19. Keywords:COVID-19, coronary heart disease, hypertension, cardiovascular system. Introduction: According to the World Health Organization (WHO), every year 17.7 million people die from coronary heart disease (CHD), which accounts for 31.1% of total mortality. This figure has increased further during the SARS-CoV2 (COVID-19) pandemic. This is because the main risk group for COVID-19 infection is people with cardiovascular diseases, in particular, a population group with arterial hypertension (AH), CHD and diabetes mellitus (DM), who are at high risk of contracting coronavirus infection, and the main risk group is directly these patients. When studying the frequency of comorbidities against the background of COVID-19, the following data were found: hypertension (HD) (53.8%), DM (42.3%), CHD(19.2%), cerebral infarction (15.4%), chronic bronchitis (19.2%) and Parkinson's disease(7.7%). In addition, acute cardiac complications from SARS-CoV2 infection increase the difficulty and complexity of treating patients. Thus, the development of cardiovascular complications in patients with pre-existing heart disease or during COVID-19 disease is a very important issue and may be a significant comorbid factor leading to death in COVID-19 page2635 INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE ISSN:2692-5206,ImpactFactor:12,23 AmericanAcademicpublishers,volume05,issue05,2025 Journal: https://www.academicpublishers.org/journals/index.php/ijai patients. COVID-19 is more severe in patients with cardiovascular disease, causing ACS complications and in somecases, death. Scientists are closely studying the pathophysiological mechanisms of the COVID-19 virus and its interaction with the human lung and heart. According to several sources, the AAF2 inhibitor located in alveolar epithelial cells serves as a carrier of SARS-CoV2 to human lung cells. The first descriptions of patients with coronavirus infection, as well as previous experience in treating patients with MERS-CoV, have led to a discussion about whether the presence of comorbidities, including IBD, is associated with an increased risk of adverse outcomes. Research methods. The studies were conducted from 2020 to 2023 in the Samarkand branch of the Republican Scientific Center for Emergency Medical Care (RSCHEMC) and the Samarkand regional branch of the Republican Specialized Scientific Medical Center for Cardiology. The studies were conducted on95patients aged 35 to75 years withHF and hypertension against the background of COVID-19. 38 of the patients were women, which made up 40.0%, and 57 were men, which made up60.0%. Patients with HF and hypertension against the background of COVID-19 had a large number of and various neurotic complaints. While most of them were symptoms of the disease, most were associated with dyscirculatory encephalopathy, a condition after cerebral circulation disorders. Attention was paid to determining the degree of depression in the disease according tothe Beck scale. The scale has 21category questions. Each question has 4answers. Depending on the manifestation of symptoms, the answers are assigned a score of 0 to 3. 0 points - no symptoms. 3 points - maximum. The questionnaire is filled out by the patient. The sum of the scores ranges from 0 to 63 points. In the assessment, 0-9 points are considered to be no depression and nervous disorders, 10-15 points - mild depression (subdepression); 16-19 points - moderate depression, 20-29 points - severe depression (moderately severe) and 30-63 points - severe depression. In our observations, the calculation of the points accumulated in 20 (21.0%) patients led to the conclusion that “no depression and nervous disorders” were observed. 75 (79.0%) patients had depression of varying degrees. Of all patients, 26 (27.4%) had mild (10-15